Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 29 of 6351
-
Could chemo plus immunotherapy double the punch against tough lung cancers?
Disease control Not yet recruitingAIO-TRK/YMO-0425 (High Five) is a phase III, open-label randomized-controlled, multicenter study to evaluate the progression-free survival by the addition of platinum-based chemotherapy to immunotherapy (IO) compared to IO monotherapy in patients with PD-L1high mNSCLC featuring a…
Phase 3 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a psychedelic ease the existential weight of advanced cancer?
Symptom relief Not yet recruitingThis pilot clinical trial will study psilocybin-assisted therapy for adults with advanced cancer who are experiencing demoralization, existential distress, or related psychological concerns. Demoralization can include feelings of hopelessness, helplessness, loss of meaning, and d…
Phase 2 • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can a new drug combo shrink liver tumors in Hard-to-Treat colorectal cancer?
Disease control Not yet recruitingThis single-arm phase II trial enrolls patients with RAS-mutant, microsatellite-stable (MSS) unresectable colorectal cancer liver metastases receiving first-line treatment with Retlirafusp alfa combined with XELOX (capecitabine plus oxaliplatin) and bevacizumab. The primary endpo…
Phase 2 • Sponsor: Dai, Guanghai • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a menin-blocking drug outsmart stubborn leukemia?
Disease control Not yet recruitingThe objective of this study is to establish the efficacy, safety, and tolerability of S243249 and to establish the recommended phase 2 dose (RP2D) of S243249 monotherapy in participants with relapsed/refractory (R/R) acute leukemia with select mutations. Phase 1 dose optimization…
Phase 1/2 • Sponsor: Servier • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new pill ease depression without Add-Ons?
Disease control Not yet recruitingThe purpose of the study is to assess how well each dose of lumateperone (Dose 1 and 2) works when given alone as compared to placebo in participants with major depressive disorder (MDD; a medical condition characterized by a persistent feeling of deep sadness, hopelessness, and …
Phase 3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a CMV-Based vaccine teach the body to fight HIV?
Vaccine Not yet recruitingThis study is to test an experimental HIV Vaccine. About 12 participants, aged 18-55 years and who already have cytomegalovirus (CMV) will take part in this study. Participants will come to the clinic for scheduled visits about 21 times over 12 months.
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 05, 2026 00:00 UTC
-
Can a 60-Minute group session and peer calls curb suicide crises?
Disease control Not yet recruitingSuicide is a major public health concern in the United States, with more than 1.4 million adults attempting suicide and nearly 50,000 adults dying by suicide each year. The launch of the national 3-digit 988 Suicide \& Crisis Lifeline in 2022 has strengthened the crisis care syst…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
A daily pill that may shield stroke patients from stomach bleeding while on blood thinners
Prevention Not yet recruitingThe goal of this clinical trial is to learn if zastaprazan can help prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or anticoagulant medications. The main question it aims to …
Phase 3 • Sponsor: Asan Medical Center • Aim: Prevention
Last updated Jul 30, 2026 00:00 UTC
-
New combo therapy aims to boost remission in Hard-to-Treat lymphoma
Disease control Not yet recruitingThe goal of this clinical trial is to assess the clinical efficacy of bridging therapy with glofitamab/gemcitabine/oxaliplatin (Glofit-GemOx) followed by lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell lymphomas. This clinical trial also aims to investigat…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a weekly shot ease sleep apnea in obesity?
Disease control Not yet recruitingUBT251 will be compared with placebo (an inactive substance identical in appearance) to evaluate its therapeutic effect in participants with moderate-to-severe obstructive sleep apnea maintained on positive airway pressure therapy.Participants will complete the following study pr…
Phase 3 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo aims to stall ovarian cancer in patients without common DNA repair flaw
Disease control Not yet recruitingThis study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab works in treating ovarian cancer compared to bevacizumab alone or active observation (AO). The study also assesses whether Mo-Rez is safe and tolerated well by…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for Hard-to-Treat endometrial cancer: pfizer launches phase 3 trial
Disease control Not yet recruitingThis study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destr…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Broader HPV shield: could a 9-Type vaccine strengthen protection after the 2-Type shot?
Vaccine Not yet recruitingResearchers want to learn if V503 (also called the 9-valent human papillomavirus \[9vHPV\] vaccine, recombinant) can induce an immune response to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Chinese females who previously received the bivalent HPV (2vHPV) vaccine. The 9vHP…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Vaccine
Last updated Sep 06, 2026 00:00 UTC
-
Can focused radiation boost Immunotherapy's power against advanced cancer?
Disease control Not yet recruitingThis is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment. SRBT will be used to treat multiple areas of cance…
Phase 2 • Sponsor: Mark Bernard • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo aims to stall advanced prostate cancer
Disease control Not yet recruitingThe primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane a…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a Rapid-Acting clot blocker boost stroke recovery?
Disease control Not yet recruitingIschemic stroke accounts for the majority of stroke cases in China, and moderate ischemic stroke (NIHSS 4-10) carries a high risk of early neurologic deterioration (END) and long-term disability. Although intensified antiplatelet strategies reduce END, they have not consistently …
Phase 4 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Mouthwash for moms: simple oral care could save thousands of tiny newborns
Prevention Not yet recruitingPeriodontal disease in pregnant women has been implicated as a potential risk factor for adverse pregnancy outcomes, including being born preterm, small-for-gestational age, and/or low birth weight. Infants who have at least one of these outcomes, known as small vulnerable newbor…
Phase 3 • Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Prevention
Last updated Jul 11, 2026 00:00 UTC
-
Can a shorter hormone therapy course be just as effective for High-Risk prostate cancer?
Disease control Not yet recruitingHigh-risk prostate cancer is usually treated with a combination of radiation therapy and hormone therapy (ADT). Radiation destroys cancer cells, while ADT lowers testosterone, a hormone that prostate cancer cells need to grow. Together, these treatments help control the cancer. …
Phase 3 • Sponsor: Dr. Tamim Niazi • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a T-Cell engager open the door to more kidney transplants?
Disease control Not yet recruitingThis investigator-initiated, single-arm, open-label Phase IIa pilot study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OM336 in highly HLA-sensitized adults with chronic kidney disease awaiting kidney transplantation. The…
Phase 2 • Sponsor: Medical University of Vienna • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Sepsis alert system aims to speed up critical care response in hospitals
Disease control Not yet recruitingSepsis is a life-threatening reaction to an infection. It can begin while a person is already in the hospital for some other reason. Sepsis that starts in the hospital is often recognized late, and treatment can be delayed. On the general wards at the study hospital, patients who…
Sponsor: Patricks Lyons • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC